Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in Duchenne Muscular Dystrophy
NCT03354039Phase 3Completed
- Sponsor
- University Hospital Basel
- Start
- Jun 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Tamoxifen with Placebo (2 arms). Primary endpoint: Reduction of disease progression at 48 weeks. Started Jun 2018; status: completed.
02
Drugs
tamoxifen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03354039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03354039.